Needham & Company Starts Cidara Therapeutics (CDTX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
Cidara Therapeutics' (CDTX) CD101 IV Granted FDA Fast-Track Designation
May 11, 2015 8:34 AM EDTCidara Therapeutics (NASDAQ: CDTX) announced that the U.S. Food and Drug Administration (FDA) has designated the companys lead antifungal product candidate, CD101 IV, as a Qualified Infectious Disease Product (QIDP) with Fast Track status. The QIDP and Fast Track designations are for the use of CD101 IV in the treatment of candidemia and invasive candidiasis.
The QIDP designation, provided under the Generating Antibiotic Incentives Now Act (GAIN Act), offers certain incentives for the development of new antibacterial or antifungal drugs, including eligibility for Fast Track, priority review and,... More
Wedbush Starts Cidara Therapeutics (CDTX) at Outperform
May 11, 2015 7:08 AM EDTWedbush initiates coverage on Cidara Therapeutics (NASDAQ: CDTX) with a Outperform rating and a price target of $22.00.
Analyst David Nierengarten commented, "CDTX is addressing the large unmet need for new antifungal agents. Systemic fungal infections are associated with high mortality and an increasingly... More
Jefferies Starts Cidara Therapeutics (CDTX) at Buy
May 11, 2015 6:41 AM EDTJefferies initiates coverage on Cidara Therapeutics (NASDAQ: CDTX) with a Buy rating and a price target of $25.00.
Analyst Eun K. Yang commented, "While early in development, CDTX provides a risk-balanced portfolio: relatively low-risk lead candidate CD101 for serious fungal infections & high-risk/high-reward Cloudbreak immunotherapy for... More
Leerink Partners Starts Cidara Therapeutics (CDTX) at Outperform
May 11, 2015 6:32 AM EDTLeerink Partners initiates coverage on Cidara Therapeutics (NASDAQ: CDTX) with a Outperform rating and a price target of $24.00, saying CD101 has the potential to be a best-in-class anti-fungal agent.
Analyst Paul Matteis commented, "Cidara is a biotechnology company that is focused on developing... More
